左心室辅助装置和当前的技术状况:5年后的HeartMate 3
Omar Jawaid1, Christopher Salerno2, Ashwin Ravichandran1
1St. Vincents' Ascension, 8333 Naab Road, Indianapolis, IN 46260, USA.
Heart failure clinics
|November 12, 2023
概括
左心室辅助器件 (LVAD) 为末期心力衰竭患者提供了一个至关重要的替代方案,当捐赠心脏稀缺时. 本综述总结了LVAD技术的进展和当前状况.
科学领域:
- 心血管医学 心血管医学
- 生物医学工程 生物医学工程
背景情况:
- 最终阶段心力衰竭需要先进的治疗选择.
- 心脏移植受到供体器官可用性的限制.
- 左心室辅助器件 (LVAD) 为等待移植或不适合移植的患者提供了关键的替代方案.
研究的目的:
- 审查目前左心室辅助器件 (LVAD) 技术的进展.
- 总结当前一代LVAD用于治疗末期心力衰竭的技术状况.
主要方法:
- 关于LVAD技术近期进展的文献综述.
- 对当前一代LVAD及其临床影响的分析.
主要成果:
- 在过去的20年里,LVAD技术取得了重大进展.
- 当前一代LVAD代表了心脏移植的可行和改进的替代方案.
结论:
- 由于捐赠者心脏的局限性,LVAD在管理末期心力衰竭方面越来越重要.
- 该审查强调了先进的LVADs的进展和当前状态.
相关概念视频
Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Cardiac Catheterization III: Left Heart Catheterization
21
Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
21
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Cardiomyopathy III: Hypertrophic Cardiomyopathy
15
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
15
Heart Failure VI: Adjunct Therapies
15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9


